News | February 24, 2026
Bayer introduces chemo-free treatment option for advanced prostate cancer in India
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Subscribe To Our Newsletter & Stay Updated
